Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-808-1 | CAS number: 12034-57-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In an acute oral toxicity study (OECD 423) with niobium oxide (target substance) no mortality has been reported at the limit dose of 2000 mg/kg bw. Thus, the oral LD50 can be considered to be greater than 2000 mg/kg bw. In an acute inhalation toxicity study according to OECD Guideline 403, groups of young adult Sprague-Dawley rats (5/sex) were exposed via the inhalation route to niobium pentoxide (source substance) as aerosol in air for 4 hours nose only at a concentration of 5.45 mg/L. Animals then were observed for 14 days. No death occurred. Based on the results a LC50 of greater than 5.45 mg/L can be considered for both sexes.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2003-01-02 to 2003-03-20
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- - Treatment of test material prior to testing: The test item was suspended in dimethylsulfoxide prior to use after crushing with a pestle and mortar to a fine dust, because there is no other suitable solvent. The suspension was carefully mixed immediately before administration. The homogeneity was proved visually.
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles RIver Wiga GmbH, 9730 Sulzfeld, Germany
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: approx. 7 weeks
- Weight at study initiation: 214.0 ± 13.3 g
- Fasting period before study: over night before oral administration
- Housing: groups of up to 3 per cage (Makrolon type 3)
- Bedding: ALTROMIN Type S8/15, granulated soft wood bedding
- Diet (e.g. ad libitum): ad libitum, ALTROMIN 1324, pelleted standard diet
- Water (e.g. ad libitum): ad libitum, tap water
- Acclimation period: 6 days before randomisation
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.0 - 21.5
- Humidity (%): 30 - 40 %, with a shortly falling below 25 %
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5 % (m/v) solution of Tylose MH 1000 in deionised water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 3 g test item filled up to 15 mL using 0.5 % (m/v) solution of Tylose MH 100 in deionised water
- Amount of vehicle (if gavage):
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg bw
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: according to the mentioned regulatory guideline the limit test should be done at one dose level of 2000 mg/kg bw - Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 6 female rats
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
- Clinical signs and mortality: continuously on administration day, once daily thereafter
- Weighing: On the day of administration and on days 7 and 14.
- Necropsy of survivors performed: yes, all animals were examined externally. The cranial, thoracic and abdominal cavities were then opened and examined macroscopically. - Statistics:
- Group mean values and standard deviations for body weights and body weight gain.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Sex:
- female
- Dose descriptor:
- LD0
- Effect level:
- 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- None
- Clinical signs:
- No signs observed
- Gross pathology:
- No findings observed
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- In conclusion, the oral LD50 in rats after treatment with niobium oxide is considered to be greater than 2000 mg/kg bw.
- Executive summary:
In an acute oral toxicity study according to OECD guideline 423, six fasted female Wistar rats were given a single oral dose of niobium oxide (>99% purity), suspended in a 0.5% (m/v) solution of Tylose MH 1000 in deionised water, at a dose of 2000 mg/kg bw (limit test) and were observed for 14 days. Neither mortality nor adverse clinical signs were recorded during the observation period. Based on the results from this study, the oral LD50 in rats is considered to be greater than 2000 mg/kg bw.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- Guideline study
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- For justification of read-across please refer to the read-across report attached to IUCLID section 13.
- Reason / purpose for cross-reference:
- read-across source
- Preliminary study:
- not applicable
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC0
- Effect level:
- > 5 450 mg/m³ air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- There were no unscheduled deaths.
- Clinical signs:
- other: During exposure: Exaggerated breathing was observed in most test rats from 1 hour, and all test rats from 2 hours into exposure. Observation period: Exaggerated breathing was observed in all test rats immediately post exposure, persisting to day 4 of the
- Body weight:
- A slightly reduced mean bodyweight gain was evident for male test rats during the first week following exposure. Thereafter, the mean bodyweight gain was similar to that of the control values. Bodyweight gain values of the female test rats were similar to that of the control values.
- Gross pathology:
- There were no treatment-related findings noted at necropsy
- Other findings:
- - Organ weights: no effects seen on lung weights
- Water consumption: no treatment-related effects were observed - Interpretation of results:
- GHS criteria not met
- Conclusions:
- The LC0 (4-hour) for diniobium pentoxide is greater than 5.45 mg/L and therefore no classification is required according to CLP.
- Executive summary:
In an acute inhalation toxicity study according to OECD Guideline 403, groups of young adult Sprague-Dawley rats (5/sex) were exposed via the inhalation route to niobium pentoxide (99.99 % purity) as aerosol in air for 4 hours nose only at a concentration of 5.45 mg/L. Animals then were observed for 14 days. No death occurred. Exaggerated breathing was observed in most test animals from the 1st hour and in all test rats from the 2nd hour of exposure. Exaggerated breath persisted until day 4 post exposure. Based on the results a LC50 of greater than 5.45 mg/L can be considered for both sexes. Niobium pentoxide is not classified according to CLP.
This information is used in a read-across approach in the assessment of the target substance.
For justification of read-across please refer to the attached read-across report (see IUCLID section 13).
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 5 450 mg/m³
- Quality of whole database:
- Guideline study
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In an acute oral toxicity study (OECD 423) with Niobium oxide (target substance) no mortality has been reported at the limit dose of 2000 mg/kg bw. Thus, the oral LD50 can be considered to be greater than 2000 mg/kg bw. No data is available for the inhalation route for the target substance. Thus, available data from Niobium pentoxide (source substance) is used to assess the acute inhalation potential of niobium oxide. For justification of read-across please refer to the read-across report attached to IUCLID section 13.
In an acute inhalation toxicity study according to OECD Guideline 403, groups of young adult Sprague-Dawley rats (5/sex) were exposed via the inhalation route to niobium pentoxide as aerosol in air for 4 hours nose only at a concentration of 5.45 mg/L. Animals then were observed for 14 days. No death occurred. Based on the results a LC50 of greater than 5.45 mg/L can be considered for both sexes.
Justification for classification or non-classification
Based on the available data, Niobium oxide does not warrant classification for acute toxicity in accordance to regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.